Articles related to CARDIOVASCULAR EVENTS

“Heart disease runs in families, so if family members have had heart attacks, there’s a good chance you’re at risk.”

Bedtime antihypertensive dosing achieved superior nocturnal blood pressure control with 79% versus 69.8% nighttime systolic control rates and required fewer dose escalations than morning administration.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

A landmark analysis shows that physiology-guided complete revascularization reduced adverse outcomes by approximately 25% compared to culprit-only strategy across both STEMI and NSTEMI patients.

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

Clinical research demonstrates that erythritol consumption increases blood levels by more than 1,000 times and enhances platelet responsiveness in healthy volunteers, potentially elevating cardiovascular risk in susceptible populations.